Bioharvest Sciences Inc. (BHST)
BioHarvest Sciences wins $1.2M fragrance contract
BioHarvest Sciences Inc (NASDAQ:BHST, FRA:8MV0) has secured a $1.2 million Stage 2 contract to develop a rare scent-producing plant compound for the global fragrance industry, marking a key step in the firm's push into a market the company values at $23 billion. The contract, awarded by a United Arab Emirates-based investment group, is part of a multi-stage development program for a fragrance raw material described as among the most valuable in the world, with premium grades fetching tens of thousands of dollars per kilogram.
Will BioHarvest Sciences Inc. (BHST) Report Negative Earnings Next Week? What You Should Know
BioHarvest Sciences Inc. (BHST) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
BioHarvest Sciences names co-founder Rakib as CEO in leadership transition
BioHarvest Sciences Inc (NASDAQ:BHST, FRA:8MV0) said on Wednesday it has appointed co-founder Dr Zaki Rakib as CEO, consolidating leadership of its research, manufacturing, and operations under a unified structure as the botanical technology company sharpens its growth strategy. Rakib, who previously served as executive chairman, will take charge of the company's contract development and manufacturing organization (CDMO) division.
BioHarvest Sciences Inc. (BHST) Reports Q4 Loss, Lags Revenue Estimates
BioHarvest Sciences Inc. (BHST) came out with a quarterly loss of $0.1 per share versus the Zacks Consensus Estimate of a loss of $0.11. This compares to a loss of $0.17 per share a year ago.
BioHarvest Sciences achieves revenue gains and margin expansion, narrows losses in 2025
BioHarvest Sciences Inc (NASDAQ:BHST, FRA:8MV0) has reported its financial results for the fourth quarter and full year 2025, highlighting revenue growth, improved margins, and continued investment in its product and contract manufacturing businesses. The company recorded full-year revenue of $34.5 million, representing a 37% increase compared to 2024.
BioHarvest Sciences advances sustainable fragrance production with rare plant breakthrough
BioHarvest Sciences Inc (NASDAQ:BHST, FRA:8MV0) announced that it has completed the first stage of a multi-phase development program focused on a rare scent-producing plant used in the global fragrance industry. The work was carried out through the company's contract development and manufacturing organization (CDMO) division under an agreement signed about a year ago.
BioHarvest Sciences' VINIA gains traction with top spot in US nutraceutical category
BioHarvest Sciences Inc (NASDAQ:BHST, FRA:8MV0) said its VINIA product has become the top-selling resveratrol polyphenol nutraceutical brand in the United States, citing company data, as it continues to expand its direct-to-consumer business. The biotechnology company attributed VINIA's market position to its clinically studied ability to support arterial dilation and blood flow, a mechanism it says can enhance oxygen and nutrient delivery throughout the body.
BioHarvest appoints former Israeli health chief Hezi Levy to board
BioHarvest Sciences Inc (NASDAQ:BHST, FRA:8MV0) said on Thursday that it has appointed former Israeli health ministry chief Hezi Levy to the board effective immediately. David Tsur will step down from its board of directors after more than four years of service, the company said in a statement.
BioHarvest Sciences CEO reflects on milestone year in shareholder letter
BioHarvest Sciences Inc (NASDAQ:BHST) said its first full year as a Nasdaq-listed company was marked by revenue growth, expanding operations, and balance sheet improvements, according to a shareholder letter released on Wednesday by CEO Ilan Sobel. In the letter, Sobel outlined operating and financial progress made in 2025 and described the company's position entering 2026.
BioHarvest gets $1.6M Israeli grant to advance botanical synthesis technology
BioHarvest Sciences Inc (NASDAQ:BHST) said on Thursday it has been awarded a $1.6 million grant from the Israeli Innovation Authority (IIA) to support the development of its second-generation Botanical Synthesis manufacturing process. The biotechnology company said the funding was approved under the IIA's Bio-Convergence program, which backs technologies combining biology, engineering, data science and artificial intelligence.
BioHarvest Sciences launches VINIA Blood Flow Hydration product in US market
BioHarvest Sciences Inc. (NASDAQ:BHST) has launched VINIA Blood Hydration, a new electrolyte product that incorporates the company's Piceid resveratrol ingredient. The launch marks BioHarvest's entry into the US hydration and electrolyte category, a market the company cites as worth about $13 billion.
BioHarvest Sciences Inc. (BHST) Q3 2025 Earnings Call Transcript
BioHarvest Sciences Inc. ( BHST ) Q3 2025 Earnings Call November 13, 2025 4:30 PM EST Company Participants Ilan Sobel - Chief Executive Officer Bar Dichter - Chief Financial Officer Conference Call Participants Matthew Hewitt - Craig-Hallum Capital Group LLC, Research Division Nicholas Sherwood - Maxim Group LLC, Research Division Susan Anderson - Canaccord Genuity Corp., Research Division Presentation Operator Greetings, and welcome to the BioHarvest Sciences Third Quarter 2025 Corporate Update Conference Call. [Operator Instructions] As a reminder, this conference is being recorded.
